A cannabinoid-based 

biopharmaceutical company.

 

We are focused on drug discovery & personalized medicine derived from plant-based therapeutics and combination therapies.

The new frontier between medicine and botany.

1

AWARDED PATENT INHIBITING AUTOPHAGY TO PREVENT & TREAT CANCER

11

PROVISIONAL PATENT TO TREAT 11 CNS-RELATED VIRUSES & DISEASES*

15

15+ CELL STUDIES  ONCOLOGY & ANTIVIRAL / CNS-RELATED VIRUSES & DISEASES 

OUR PIPELINE

Clinical Trial

DCIS Breast Cancer & Cannabinoids

First & only company to be awarded a patent that includes using any molecule, including cannabinoids, as an autophagy inhibitor.  Several cell studies and clinical trial with live breast cancer patients. 

ONGOING - PHASE I / II

Clinical Trial

HIV Associated Dementia & Cannabinoids

Several cell studies on the use of cannabinoids to treat HIV affiliated dementia  and other central nervous system (CNS) diseases and viruses.

ONGOING - PHASE I / II

Pre-Clinical

Anti-viral Studies to Treat Sepsis

Pre-clinical ant-viral research includes COVID related Sepsis work within a BSL-3 laboratory managed by George Mason University.  Focused on using synthetic cannabinoid-based therapeutics to treating Sepsis and infectious diseases.

ONGOING

 

MEET TARGETED PHARMACEUTICALS 

OUR VISION

Our goal is to bring precision medicine and real science to the cannabis industry by linking the molecular structure of humans to cannabinoid compounds.

DATA DRIVEN SOLUTIONS

Technology and data are at the core of what we do.  We are very much a data-driven technology company focused on using data for personalized cannabinoid care.     

 

TOP TEAM & ADVISORS FROM 

 

TOP TEAM & ADVISORS FROM 

George Mason University

National Cancer Institute

Harvard University 

Worcester Polytechnic Institute

McLean Hospital

Food & Drug Adminstration

LATEST NEWS

Oct 22, 2020

Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19

  • Targeted Pharmaceuticals, Tetra Bio-Pharma and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration
     

  • ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is excited to announce that it has signed a research collaboration agreement with Targeted Pharmaceutical and the George Mason University.  The research is being conducted at the Biomedical Research Laboratory (BRL) which is managed by the George Mason University National Center for Biodefense and Infectious Diseases (NCBID)

 

GET

IN TOUCH

Targeted Pharmaceuticals
11 Apex Drive, Suite 300A
Marlborough, MA 01752

Targeted Pharmaceuticals is a cannabinoid-based drug discovery company.

Contact us today to learn more. 
 

© 2018-2019 Targeted Pharmaceuticals, LLC

Image Copyright credit: www.gmu.edu